{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:54:02Z","timestamp":1782276842350,"version":"3.54.5"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC2145 SyNergy \u2013 ID 390857198"],"award-info":[{"award-number":["EXC2145 SyNergy \u2013 ID 390857198"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["263531414 \/ FOR2290"],"award-info":[{"award-number":["263531414 \/ FOR2290"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006312","name":"BrightFocus Foundation","doi-asserted-by":"publisher","award":["ADR AD2019604S"],"award-info":[{"award-number":["ADR AD2019604S"]}],"id":[{"id":"10.13039\/100006312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Amyloid-\u03b2 peptide (A\u03b2) species of 42 or 43 amino acids in length (A\u03b242\/43) trigger Alzheimer\u00b4s disease (AD) and are produced in abnormal amounts by mutants of the \u03b3-secretase subunit presenilin-1 (PS1), which represent the primary cause of familial AD (FAD). Lowering these peptides by \u03b3-secretase modulators (GSMs) is increasingly considered a safe strategy to treat AD since these compounds do not affect the overall cleavage of \u03b3-secretase substrates. GSMs were shown to modulate not only wild-type (WT) \u03b3-secretase but also FAD mutants, expanding their potential use also to the familial form of the disease. Unlike most other FAD mutants, the very aggressive PS1 L166P mutant is largely resistant to GSMs. However, these data were mostly obtained from overexpression models, which mimic more the less relevant homozygous state rather than the heterozygous patient situation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Mouse embryonic fibroblast and induced pluripotent stem cell-derived neuronal PS1 L166P knock-in (KI) cell models were treated with various GSMs and A\u03b2 responses were assessed by immunoassays and\/or gel-based analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We identified GSMs that lower A\u03b242 and\/or A\u03b243 when PS1 L166P is heterozygous, as it is the case in affected patients, and could reduce the amount of pathogenic A\u03b2 species towards WT levels. RO7019009 was the most potent of these compounds, reducing both pathogenic species and concomitantly increasing the short A\u03b237 and A\u03b238, of which the latter has been associated with delayed AD progression. Another effective compound, the structurally novel indole-type GSM RO5254601 specifically acts on the A\u03b242 product line leading to a selective increase of the beneficial A\u03b238. Interestingly, we further found that this class of GSMs can bind not only one, but both presenilin fragments suggesting that it targets \u03b3-secretase at an unusual binding site.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our data show that even highly refractory presenilin FAD mutants are in principle tractable with GSMs extending the possibilities for potential clinical studies in FAD with suitable GSM molecules.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13195-025-01680-3","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:06:26Z","timestamp":1739963186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["\u03b3-Secretase modulator resistance of an aggressive Alzheimer-causing presenilin mutant can be overcome in the heterozygous patient state by a set of advanced compounds"],"prefix":"10.1186","volume":"17","author":[{"given":"Johannes","family":"Trambauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria Rodriguez","family":"Sarmiento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly J.","family":"Garringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Salbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana D.","family":"Pedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Crusius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardino","family":"Ghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Paquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlheinz","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"1680_CR1","doi-asserted-by":"publisher","first-page":"a004457","DOI":"10.1101\/cshperspect.a004457","volume":"3","author":"DJ Selkoe","year":"2011","unstructured":"Selkoe DJ. Alzheimer\u2019s disease. Cold Spring Harb Perspect Biol. 2011;3:a004457.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1680_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8:595\u2013608.","journal-title":"EMBO Mol Med"},{"key":"1680_CR3","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/j.1471-4159.2011.07248.x","volume":"117","author":"SF Lichtenthaler","year":"2011","unstructured":"Lichtenthaler SF, Haass C, Steiner H. Regulated intramembrane proteolysis\u2013lessons from amyloid precursor protein processing. J Neurochem. 2011;117:779\u201396.","journal-title":"J Neurochem"},{"key":"1680_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.15698\/cst2018.11.162","volume":"2","author":"H Steiner","year":"2018","unstructured":"Steiner H, Fukumori A, Tagami S, Okochi M. Making the final cut: pathogenic amyloid \u03b2-peptide generation by \u03b3-secretase. Cell Stress. 2018;2:292\u2013310.","journal-title":"Cell Stress"},{"key":"1680_CR5","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1523\/JNEUROSCI.1575-04.2005","volume":"25","author":"Y Qi-Takahara","year":"2005","unstructured":"Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, Horikoshi Y, et al. Longer forms of amyloid \u03b2 protein: implications for the mechanism of intramembrane cleavage by \u03b3-secretase. J Neurosci. 2005;25:436\u201345.","journal-title":"J Neurosci"},{"key":"1680_CR6","doi-asserted-by":"publisher","first-page":"13042","DOI":"10.1523\/JNEUROSCI.2362-09.2009","volume":"29","author":"M Takami","year":"2009","unstructured":"Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, et al. \u03b3-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of \u03b2-carboxyl terminal fragment. J Neurosci. 2009;29:13042\u201352.","journal-title":"J Neurosci"},{"key":"1680_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.celrep.2012.11.028","volume":"3","author":"M Okochi","year":"2013","unstructured":"Okochi M, Tagami S, Yanagida K, Takami M, Kodama TS, Mori K, et al. \u03b3-Secretase modulators and presenilin 1 mutants act differently on presenilin\/\u03b3-secretase function to cleave A\u03b242 and A\u03b243. Cell Rep. 2013;3:42\u201351.","journal-title":"Cell Rep"},{"key":"1680_CR8","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1038\/emboj.2012.79","volume":"31","author":"L Chavez-Gutierrez","year":"2012","unstructured":"Chavez-Gutierrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, et al. The mechanism of \u03b3-secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31:2261\u201374.","journal-title":"EMBO J"},{"key":"1680_CR9","doi-asserted-by":"publisher","first-page":"31043","DOI":"10.1074\/jbc.M114.581165","volume":"289","author":"MA Fernandez","year":"2014","unstructured":"Fernandez MA, Klutkowski JA, Freret T, Wolfe MS. Alzheimer presenilin-1 mutations dramatically reduce trimming of long amyloid \u03b2-peptides (A\u03b2) by \u03b3-secretase to increase 42-to-40-residue A\u03b2. J Biol Chem. 2014;289:31043\u201352.","journal-title":"J Biol Chem"},{"key":"1680_CR10","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid \u03b2-protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease. Nat Med. 1996;2:864\u201370.","journal-title":"Nat Med"},{"key":"1680_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/alz.12646","volume":"19","author":"L Liu","year":"2023","unstructured":"Liu L, Lauro BM, He A, Lee H, Bhattarai S, Wolfe MS, et al. Identification of the A\u03b237\/42 peptide ratio in CSF as an improved A\u03b2 biomarker for Alzheimer\u2019s disease. Alzheimers Dement. 2023;19:79\u201396.","journal-title":"Alzheimers Dement"},{"key":"1680_CR12","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1038\/s41380-022-01518-6","volume":"27","author":"D Petit","year":"2022","unstructured":"Petit D, Fernandez SG, Zoltowska KM, Enzlein T, Ryan NS, O\u2019Connor A, et al. A\u03b2 profiles generated by Alzheimer\u2019s disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset. Mol Psychiatry. 2022;27:2821\u201332.","journal-title":"Mol Psychiatry"},{"key":"1680_CR13","first-page":"e958","volume":"98","author":"N Cullen","year":"2021","unstructured":"Cullen N, Janelidze S, Palmqvist S, Stomrud E, Mattsson-Carlgren N, Hansson O. Association of CSF A\u03b238 levels with risk of Alzheimer disease-related decline. Neurology. 2021;98:e958\u201367.","journal-title":"Neurology"},{"key":"1680_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/35102591","volume":"414","author":"S Weggen","year":"2001","unstructured":"Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic A\u03b242 independently of cyclooxygenase activity. Nature. 2001;414:212\u20136.","journal-title":"Nature"},{"key":"1680_CR15","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.neuron.2010.08.018","volume":"67","author":"MZ Kounnas","year":"2010","unstructured":"Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, et al. Modulation of \u03b3-secretase reduces \u03b2-amyloid deposition in a transgenic mouse model of Alzheimer\u2019s disease. Neuron. 2010;67:769\u201380.","journal-title":"Neuron"},{"key":"1680_CR16","doi-asserted-by":"publisher","first-page":"e47996","DOI":"10.15252\/embr.201947996","volume":"21","author":"J Trambauer","year":"2020","unstructured":"Trambauer J, Rodriguez Sarmiento RM, Fukumori A, Feederle R, Baumann K, Steiner H. A\u03b243-producing PS1 FAD mutants cause altered substrate interactions and respond to \u03b3-secretase modulation. EMBO Rep. 2020;21:e47996.","journal-title":"EMBO Rep"},{"key":"1680_CR17","doi-asserted-by":"publisher","first-page":"7389","DOI":"10.1021\/acs.jmedchem.5b01960","volume":"59","author":"MG Bursavich","year":"2016","unstructured":"Bursavich MG, Harrison BA, Blain JF. \u03b3-Secretase modulators: new Alzheimer\u2019s drugs on the horizon? J Med Chem. 2016;59:7389\u2013409.","journal-title":"J Med Chem"},{"key":"1680_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/cpt.1570","volume":"107","author":"JE Ahn","year":"2019","unstructured":"Ahn JE, Carrieri C, Dela Cruz F, Fullerton T, Hajos-Korcsok E, He P, et al. Pharmacokinetic and pharmacodynamic effects of a \u03b3-secretase modulator, PF-06648671, on CSF amyloid-\u03b2 peptides in randomized Phase 1 studies. Clin Pharmacol Ther. 2019;107:211\u201320.","journal-title":"Clin Pharmacol Ther"},{"key":"1680_CR19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.trci.2019.06.006","volume":"5","author":"MZ Kounnas","year":"2019","unstructured":"Kounnas MZ, Durakoglugil MS, Herz J, Comer WT. NGP 555, a \u03b3-secretase modulator, shows a beneficial shift in the ratio of amyloid biomarkers in human cerebrospinal fluid at safe doses. Alzheimers Dement (N Y). 2019;5:458\u201367.","journal-title":"Alzheimers Dement (N Y)"},{"key":"1680_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.conb.2020.01.011","volume":"61","author":"J Trambauer","year":"2020","unstructured":"Trambauer J, Fukumori A, Steiner H. Pathogenic A\u03b2 generation in familial Alzheimer\u2019s disease: novel mechanistic insights and therapeutic implications. Curr Opin Neurobiol. 2020;61:73\u201381.","journal-title":"Curr Opin Neurobiol"},{"key":"1680_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1523\/JNEUROSCI.4849-06.2007","volume":"27","author":"J Kim","year":"2007","unstructured":"Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, et al. A\u03b240 inhibits amyloid deposition in vivo. J Neurosci. 2007;27:627\u201333.","journal-title":"J Neurosci"},{"key":"1680_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1084\/jem.20170600","volume":"215","author":"BD Moore","year":"2018","unstructured":"Moore BD, Martin J, de Mena L, Sanchez J, Cruz PE, Ceballos-Diaz C, et al. Short A\u03b2 peptides attenuate A\u03b242 toxicity in vivo. J Exp Med. 2018;215:283\u2013301.","journal-title":"J Exp Med"},{"key":"1680_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41598-020-80164-w","volume":"11","author":"MO Quartey","year":"2021","unstructured":"Quartey MO, Nyarko JNK, Maley JM, Barnes JR, Bolanos MAC, Heistad RM, et al. The A\u03b2(1\u201338) peptide is a negative regulator of the A\u03b2(1\u201342) peptide implicated in Alzheimer disease progression. Sci Rep. 2021;11:431.","journal-title":"Sci Rep"},{"key":"1680_CR24","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1039\/D1SC02990H","volume":"13","author":"GA Braun","year":"2022","unstructured":"Braun GA, Dear AJ, Sanagavarapu K, Zetterberg H, Linse S. Amyloid-\u03b2 peptide 37, 38 and 40 individually and cooperatively inhibit amyloid-\u03b2 42 aggregation. Chem Sci. 2022;13:2423\u201339.","journal-title":"Chem Sci"},{"key":"1680_CR25","doi-asserted-by":"publisher","first-page":"15240","DOI":"10.1074\/jbc.M110.213587","volume":"286","author":"B Kretner","year":"2011","unstructured":"Kretner B, Fukumori A, Gutsmiedl A, Page RM, Luebbers T, Galley G, et al. Attenuated A\u03b242 responses to low potency \u03b3-secretase modulators can be overcome for many pathogenic presenilin mutants by second-generation compounds. J Biol Chem. 2011;286:15240\u201351.","journal-title":"J Biol Chem"},{"key":"1680_CR26","doi-asserted-by":"publisher","first-page":"8025","DOI":"10.1073\/pnas.112686799","volume":"99","author":"T Moehlmann","year":"2002","unstructured":"Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, Capell A, et al. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on A\u03b242 production. Proc Natl Acad Sci USA. 2002;99:8025\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1680_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1471-4159.2010.07118.x","volume":"116","author":"S Hahn","year":"2011","unstructured":"Hahn S, Bruning T, Ness J, Czirr E, Baches S, Gijsen H, et al. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer\u2019s disease attenuate the response of cultured cells to \u03b3-secretase modulators regardless of their potency and structure. J Neurochem. 2011;116:385\u201395.","journal-title":"J Neurochem"},{"key":"1680_CR28","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.neuron.2019.07.010","volume":"104","author":"D Kwart","year":"2019","unstructured":"Kwart D, Gregg A, Scheckel C, Murphy E, Paquet D, Duffield M, et al. A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP \u03b2-CTFs, not A\u03b2. Neuron. 2019;104:256-70.e5.","journal-title":"Neuron"},{"key":"1680_CR29","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/j.ajpath.2012.02.012","volume":"180","author":"P Koch","year":"2012","unstructured":"Koch P, Tamboli IY, Mertens J, Wunderlich P, Ladewig J, Stuber K, et al. Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of \u03b3-secretase activity in endogenous amyloid-\u03b2 generation. Am J Pathol. 2012;180:2404\u201316.","journal-title":"Am J Pathol"},{"key":"1680_CR30","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1021\/bi801204g","volume":"48","author":"E Winkler","year":"2009","unstructured":"Winkler E, Hobson S, Fukumori A, Dumpelfeld B, Luebbers T, Baumann K, et al. Purification, pharmacological modulation, and biochemical characterization of interactors of endogenous human \u03b3-secretase. Biochemistry. 2009;48:1183\u201397.","journal-title":"Biochemistry"},{"key":"1680_CR31","doi-asserted-by":"publisher","first-page":"28415","DOI":"10.1074\/jbc.272.45.28415","volume":"272","author":"G Thinakaran","year":"1997","unstructured":"Thinakaran G, Harris CL, Ratovitski T, Davenport F, Slunt HH, Price DL, et al. Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors. J Biol Chem. 1997;272:28415\u201322.","journal-title":"J Biol Chem"},{"key":"1680_CR32","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1523\/JNEUROSCI.5354-05.2006","volume":"26","author":"A Yamasaki","year":"2006","unstructured":"Yamasaki A, Eimer S, Okochi M, Smialowska A, Kaether C, Baumeister R, et al. The GxGD motif of presenilin contributes to catalytic function and substrate identification of \u03b3-secretase. J Neurosci. 2006;26:3821\u20138.","journal-title":"J Neurosci"},{"key":"1680_CR33","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.nbd.2007.04.011","volume":"27","author":"K Shirotani","year":"2007","unstructured":"Shirotani K, Tomioka M, Kremmer E, Haass C, Steiner H. Pathological activity of familial Alzheimer\u2019s disease-associated mutant presenilin can be executed by six different \u03b3-secretase complexes. Neurobiol Dis. 2007;27:102\u20137.","journal-title":"Neurobiol Dis"},{"key":"1680_CR34","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.1073\/pnas.94.10.5349","volume":"94","author":"J Walter","year":"1997","unstructured":"Walter J, Grunberg J, Capell A, Pesold B, Schindzielorz A, Citron M, et al. Proteolytic processing of the Alzheimer disease-associated presenilin-1 generates an in vivo substrate for protein kinase C. Proc Natl Acad Sci USA. 1997;94:5349\u201354.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1680_CR35","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1046\/j.1471-4159.1997.69062432.x","volume":"69","author":"A Capell","year":"1997","unstructured":"Capell A, Saffrich R, Olivo JC, Meyn L, Walter J, Grunberg J, et al. Cellular expression and proteolytic processing of presenilin proteins is developmentally regulated during neuronal differentiation. J Neurochem. 1997;69:2432\u201340.","journal-title":"J Neurochem"},{"key":"1680_CR36","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1096\/fj.12-205542","volume":"26","author":"R Vidal","year":"2012","unstructured":"Vidal R, Sammeta N, Garringer HJ, Sambamurti K, Miravalle L, Lamb BT, et al. The Psen1-L166P-knock-in mutation leads to amyloid deposition in human wild-type amyloid precursor protein YAC transgenic mice. FASEB J. 2012;26:2899\u2013910.","journal-title":"FASEB J"},{"key":"1680_CR37","doi-asserted-by":"publisher","first-page":"28669","DOI":"10.1074\/jbc.274.40.28669","volume":"274","author":"H Steiner","year":"1999","unstructured":"Steiner H, Duff K, Capell A, Romig H, Grim MG, Lincoln S, et al. A loss of function mutation of presenilin-2 interferes with amyloid \u03b2-peptide production and Notch signaling. J Biol Chem. 1999;274:28669\u201373.","journal-title":"J Biol Chem"},{"key":"1680_CR38","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/mp.2015.74","volume":"20","author":"M Brendel","year":"2015","unstructured":"Brendel M, Jaworska A, Herms J, Trambauer J, Rotzer C, Gildehaus FJ, et al. Amyloid-PET predicts inhibition of de novo plaque formation upon chronic \u03b3-secretase modulator treatment. Mol Psychiatry. 2015;20:1179\u201387.","journal-title":"Mol Psychiatry"},{"key":"1680_CR39","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.stemcr.2015.09.004","volume":"5","author":"L Ordovas","year":"2015","unstructured":"Ordovas L, Boon R, Pistoni M, Chen Y, Wolfs E, Guo W, et al. Efficient recombinase-mediated cassette exchange in hPSCs to study the hepatocyte lineage reveals AAVS1 locus-mediated transgene inhibition. Stem Cell Rep. 2015;5:918\u201331.","journal-title":"Stem Cell Rep"},{"key":"1680_CR40","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/s41596-020-00481-2","volume":"16","author":"I Weisheit","year":"2021","unstructured":"Weisheit I, Kroeger JA, Malik R, Wefers B, Lichtner P, Wurst W, et al. Simple and reliable detection of CRISPR-induced on-target effects by qgPCR and SNP genotyping. Nat Protoc. 2021;16:1714\u201339.","journal-title":"Nat Protoc"},{"key":"1680_CR41","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.stemcr.2017.12.014","volume":"10","author":"JA Garcia-Leon","year":"2018","unstructured":"Garcia-Leon JA, Kumar M, Boon R, Chau D, One J, Wolfs E, et al. SOX10 single transcription factor-based fast and efficient generation of oligodendrocytes from human pluripotent stem cells. Stem Cell Rep. 2018;10:655\u201372.","journal-title":"Stem Cell Rep"},{"key":"1680_CR42","doi-asserted-by":"publisher","first-page":"107689","DOI":"10.1016\/j.celrep.2020.107689","volume":"31","author":"I Weisheit","year":"2020","unstructured":"Weisheit I, Kroeger JA, Malik R, Klimmt J, Crusius D, Dannert A, et al. Detection of deleterious on-target effects after HDR-mediated CRISPR editing. Cell Rep. 2020;31:107689.","journal-title":"Cell Rep"},{"key":"1680_CR43","doi-asserted-by":"publisher","first-page":"W242","DOI":"10.1093\/nar\/gky354","volume":"46","author":"JP Concordet","year":"2018","unstructured":"Concordet JP, Haeussler M. CRISPOR: intuitive guide selection for CRISPR\/Cas9 genome editing experiments and screens. Nucleic Acids Res. 2018;46:W242\u20135.","journal-title":"Nucleic Acids Res"},{"key":"1680_CR44","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nprot.2016.171","volume":"12","author":"D Kwart","year":"2017","unstructured":"Kwart D, Paquet D, Teo S, Tessier-Lavigne M. Precise and efficient scarless genome editing in stem cells using CORRECT. Nat Protoc. 2017;12:329\u201354.","journal-title":"Nat Protoc"},{"key":"1680_CR45","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34:184\u201391.","journal-title":"Nat Biotechnol"},{"key":"1680_CR46","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuron.2013.05.029","volume":"78","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron. 2013;78:785\u201398.","journal-title":"Neuron"},{"key":"1680_CR47","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.stemcr.2017.08.019","volume":"9","author":"C Wang","year":"2017","unstructured":"Wang C, Ward ME, Chen R, Liu K, Tracy TE, Chen X, et al. Scalable production of iPSC-derived human neurons to identify Tau-lowering compounds by high-content screening. Stem Cell Rep. 2017;9:1221\u201333.","journal-title":"Stem Cell Rep"},{"key":"1680_CR48","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1074\/jbc.M708754200","volume":"283","author":"RM Page","year":"2008","unstructured":"Page RM, Baumann K, Tomioka M, Perez-Revuelta BI, Fukumori A, Jacobsen H, et al. Generation of A\u03b238 and A\u03b242 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and \u03b3-secretase modulation. J Biol Chem. 2008;283:677\u201383.","journal-title":"J Biol Chem"},{"key":"1680_CR49","doi-asserted-by":"publisher","first-page":"37181","DOI":"10.1074\/jbc.C111.276972","volume":"286","author":"A Ebke","year":"2011","unstructured":"Ebke A, Luebbers T, Fukumori A, Shirotani K, Haass C, Baumann K, et al. Novel \u03b3-secretase enzyme modulators directly target presenilin protein. J Biol Chem. 2011;286:37181\u20136.","journal-title":"J Biol Chem"},{"key":"1680_CR50","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1124\/jpet.117.240861","volume":"362","author":"SL Wagner","year":"2017","unstructured":"Wagner SL, Rynearson KD, Duddy SK, Zhang C, Nguyen PD, Becker A, et al. Pharmacological and toxicological properties of the potent oral \u03b3-secretase modulator BPN-15606. J Pharmacol Exp Ther. 2017;362:31\u201344.","journal-title":"J Pharmacol Exp Ther"},{"key":"1680_CR51","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/embo-reports\/kve180","volume":"2","author":"M Sastre","year":"2001","unstructured":"Sastre M, Steiner H, Fuchs K, Capell A, Multhaup G, Condron MM, et al. Presenilin-dependent \u03b3-secretase processing of \u03b2-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep. 2001;2:835\u201341.","journal-title":"EMBO Rep"},{"key":"1680_CR52","doi-asserted-by":"publisher","first-page":"458","DOI":"10.15252\/emmm.201505952","volume":"8","author":"B Kretner","year":"2016","unstructured":"Kretner B, Trambauer J, Fukumori A, Mielke J, Kuhn PH, Kremmer E, et al. Generation and deposition of A\u03b243 by the virtually inactive presenilin-1 L435F mutant contradicts the presenilin loss-of-function hypothesis of Alzheimer\u2019s disease. EMBO Mol Med. 2016;8:458\u201365.","journal-title":"EMBO Mol Med"},{"key":"1680_CR53","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nn.2858","volume":"14","author":"T Saito","year":"2011","unstructured":"Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, et al. Potent amyloidogenicity and pathogenicity of A\u03b243. Nat Neurosci. 2011;14:1023\u201332.","journal-title":"Nat Neurosci"},{"key":"1680_CR54","doi-asserted-by":"publisher","first-page":"17798","DOI":"10.1074\/jbc.M110.103283","volume":"285","author":"RM Page","year":"2010","unstructured":"Page RM, Gutsmiedl A, Fukumori A, Winkler E, Haass C, Steiner H. \u03b2-Amyloid precursor protein mutants respond to \u03b3-secretase modulators. J Biol Chem. 2010;285:17798\u2013810.","journal-title":"J Biol Chem"},{"key":"1680_CR55","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/elps.1150180332","volume":"18","author":"J Wiltfang","year":"1997","unstructured":"Wiltfang J, Smirnov A, Schnierstein B, Kelemen G, Matthies U, Klafki HW, et al. Improved electrophoretic separation and immunoblotting of \u03b2-amyloid (A\u03b2) peptides 1\u201340, 1\u201342, and 1\u201343. Electrophoresis. 1997;18:527\u201332.","journal-title":"Electrophoresis"},{"key":"1680_CR56","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/ncb960","volume":"5","author":"D Edbauer","year":"2003","unstructured":"Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of \u03b3-secretase activity. Nat Cell Biol. 2003;5:486\u20138.","journal-title":"Nat Cell Biol"},{"key":"1680_CR57","doi-asserted-by":"publisher","first-page":"8698","DOI":"10.1021\/bi0005456","volume":"39","author":"MS Shearman","year":"2000","unstructured":"Shearman MS, Beher D, Clarke EE, Lewis HD, Harrison T, Hunt P, et al. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid \u03b2-protein precursor \u03b3-secretase activity. Biochemistry. 2000;39:8698\u2013704.","journal-title":"Biochemistry"},{"key":"1680_CR58","unstructured":"Hannam JC, Kulagowski JJ, Madin A, Ridgill MP, Steward EM. Piperidines and related compounds for treatment of Alzheimer\u00b4s disease. International Patent WO2006\/043064. V. PCT Int. Appl. 2006. April 24, 2006."},{"key":"1680_CR59","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/toxsci\/kfh254","volume":"82","author":"J Milano","year":"2004","unstructured":"Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, et al. Modulation of Notch processing by \u03b3-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci. 2004;82:341\u201358.","journal-title":"Toxicol Sci"},{"key":"1680_CR60","doi-asserted-by":"publisher","first-page":"17049","DOI":"10.1074\/jbc.M802912200","volume":"283","author":"E Czirr","year":"2008","unstructured":"Czirr E, Cottrell BA, Leuchtenberger S, Kukar T, Ladd TB, Esselmann H, et al. Independent generation of A\u03b242 and A\u03b238 peptide species by \u03b3-secretase. J Biol Chem. 2008;283:17049\u201354.","journal-title":"J Biol Chem"},{"key":"1680_CR61","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nature17664","volume":"533","author":"D Paquet","year":"2016","unstructured":"Paquet D, Kwart D, Chen A, Sproul A, Jacob S, Teo S, et al. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR\/Cas9. Nature. 2016;533:125\u20139.","journal-title":"Nature"},{"key":"1680_CR62","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1001\/jamaneurol.2014.2482","volume":"71","author":"Q Liu","year":"2014","unstructured":"Liu Q, Waltz S, Woodruff G, Ouyang J, Israel MA, Herrera C, et al. Effect of potent \u03b3-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. JAMA Neurol. 2014;71:1481\u20139.","journal-title":"JAMA Neurol"},{"key":"1680_CR63","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.celrep.2015.03.068","volume":"11","author":"S Moore","year":"2015","unstructured":"Moore S, Evans LD, Andersson T, Portelius E, Smith J, Dias TB, et al. APP metabolism regulates tau proteostasis in human cerebral cortex neurons. Cell Rep. 2015;11:689\u201396.","journal-title":"Cell Rep"},{"key":"1680_CR64","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1084\/jem.20150892","volume":"212","author":"M Szaruga","year":"2015","unstructured":"Szaruga M, Veugelen S, Benurwar M, Lismont S, Sepulveda-Falla D, Lleo A, et al. Qualitative changes in human \u03b3-secretase underlie familial Alzheimer\u2019s disease. J Exp Med. 2015;212:2003\u201313.","journal-title":"J Exp Med"},{"key":"1680_CR65","doi-asserted-by":"publisher","first-page":"31831","DOI":"10.1074\/jbc.M303592200","volume":"278","author":"S Weggen","year":"2003","unstructured":"Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid \u03b242 production by direct modulation of \u03b3-secretase activity. J Biol Chem. 2003;278:31831\u20137.","journal-title":"J Biol Chem"},{"key":"1680_CR66","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3233\/JAD-190442","volume":"73","author":"O Prikhodko","year":"2020","unstructured":"Prikhodko O, Rynearson KD, Sekhon T, Mante MM, Nguyen PD, Rissman RA, et al. The GSM BPN-15606 as a potential candidate for preventative therapy in Alzheimer\u2019s disease. J Alzheimers Dis. 2020;73:1541\u201354.","journal-title":"J Alzheimers Dis"},{"key":"1680_CR67","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/alz.12553","volume":"18","author":"AB Caldwell","year":"2022","unstructured":"Caldwell AB, Liu Q, Zhang C, Schroth GP, Galasko DR, Rynearson KD, et al. Endotype reversal as a novel strategy for screening drugs targeting familial Alzheimer\u2019s disease. Alzheimers Dement. 2022;18:2117\u201330.","journal-title":"Alzheimers Dement"},{"key":"1680_CR68","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.1038\/emboj.2011.372","volume":"30","author":"Y Ohki","year":"2011","unstructured":"Ohki Y, Higo T, Uemura K, Shimada N, Osawa S, Berezovska O, et al. Phenylpiperidine-type \u03b3-secretase modulators target the transmembrane domain 1 of presenilin 1. EMBO J. 2011;30:4815\u201324.","journal-title":"EMBO J"},{"key":"1680_CR69","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1021\/cn200098p","volume":"2","author":"CJ Crump","year":"2011","unstructured":"Crump CJ, Fish BA, Castro SV, Chau DM, Gertsik N, Ahn K, et al. Piperidine acetic acid based \u03b3-secretase modulators directly bind to Presenilin-1. ACS Chem Neurosci. 2011;2:705\u201310.","journal-title":"ACS Chem Neurosci"},{"key":"1680_CR70","doi-asserted-by":"publisher","first-page":"e30484","DOI":"10.1371\/journal.pone.0030484","volume":"7","author":"T Jumpertz","year":"2012","unstructured":"Jumpertz T, Rennhack A, Ness J, Baches S, Pietrzik CU, Bulic B, et al. Presenilin is the molecular target of acidic \u03b3-secretase modulators in living cells. PLoS One. 2012;7:e30484.","journal-title":"PLoS One"},{"key":"1680_CR71","doi-asserted-by":"publisher","first-page":"9710","DOI":"10.1074\/jbc.M112.398602","volume":"288","author":"N Pozdnyakov","year":"2013","unstructured":"Pozdnyakov N, Murrey HE, Crump CJ, Pettersson M, Ballard TE, Am Ende CW, et al. \u03b3-Secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin. J Biol Chem. 2013;288:9710\u201320.","journal-title":"J Biol Chem"}],"updated-by":[{"DOI":"10.1186\/s13195-025-01723-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000}}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01680-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01680-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01680-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T07:02:27Z","timestamp":1744786947000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01680-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1680"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01680-3","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13195-025-01723-9","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article was revised to load the missing Supplementary file 14 e-file: the e-files in the Supplementary Information section were out of sync resulting in the missing Supplementary material 14 e-file.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13195-025-01723-9","URL":"https:\/\/doi.org\/10.1186\/s13195-025-01723-9","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments were performed in accordance with all relevant guidelines and regulations. Female iPSC line A18944 was purchased from ThermoFisher (A18945). No human subjects were involved in this study; confirmation of consent was not necessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H.S. has received research funding from Roche. D.P. is a scientific advisor of ISAR Bioscience. R.M.R.S., K.B., and L.L. are full-time employees of F. Hoffmann-La Roche AG, are inventors of patents in the name of F. Hoffmann-La Roche AG, and might own stocks \/ stock options of F. Hoffmann-La Roche AG. All other authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}